Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 6276Carcinoma, Renal Cell 1915Urinary Bladder Neoplasms 1672Kidney Neoplasms 931Breast Neoplasms 794Neoplasms 791Carcinoma, Transitional Cell 597Carcinoma, Non-Small-Cell Lung 525Neoplasm Metastasis 511Melanoma 486Ovarian Neoplasms 470Colorectal Neoplasms 456Lung Neoplasms 436Pancreatic Neoplasms 326Testicular Neoplasms 290Stomach Neoplasms 274Sarcoma 267Uterine Cervical Neoplasms 265Non-Muscle Invasive Bladder Neoplasms 264Head and Neck Neoplasms 242Colonic Neoplasms 217Esophageal Neoplasms 203Squamous Cell Carcinoma of Head and Neck 202Carcinoma, Hepatocellular 200Wilms Tumor 196Endometrial Neoplasms 191Recurrence 162Urologic Neoplasms 149Neuroblastoma 148Small Cell Lung Carcinoma 146

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Metastatic Hormone Refractory Prostate Cancer × Genitourinary × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00766324 2014-05-28

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Nerviano Medical Sciences

Phase 2 Completed
118 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00636090 2013-12-04

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Duke University

Completed
35 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡